<DOC>
	<DOCNO>NCT01582737</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , local prospective observational study patient receive Xarelto SPAF . The objective study ass safety effectiveness Xarelto use real clinical practice . A total 10,000 patient enrol assessed 2 year standard observational period . An annual follow-up survey conduct 5 year longest standard observational period .</brief_summary>
	<brief_title>Xarelto SPAF Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients receive Xarelto SPAF Patients without experience use Xarelto prior study Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Xarelto</keyword>
	<keyword>SPAF</keyword>
</DOC>